qPULA Trading Management LP Sells 283 Shares of Johnson & Johnson (NYSE:JNJ)

qPULA Trading Management LP reduced its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 11.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,100 shares of the company’s stock after selling 283 shares during the period. Johnson & Johnson comprises 1.4% of qPULA Trading Management LP’s investment portfolio, making the stock its 27th largest holding. qPULA Trading Management LP’s holdings in Johnson & Johnson were worth $373,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 1.4% during the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after purchasing an additional 3,358,478 shares during the last quarter. GQG Partners LLC grew its holdings in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares during the last quarter. Swiss National Bank grew its holdings in shares of Johnson & Johnson by 14.0% during the first quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock worth $2,020,868,000 after purchasing an additional 1,396,500 shares during the last quarter. Finally, Bridgewater Associates LP lifted its stake in shares of Johnson & Johnson by 40.3% in the first quarter. Bridgewater Associates LP now owns 4,345,002 shares of the company’s stock worth $770,065,000 after acquiring an additional 1,247,260 shares during the period. 68.59% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at $18,864,202. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the sale, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The disclosure for this sale can be found here. Insiders have sold 212,646 shares of company stock valued at $36,791,022 over the last ninety days. 0.35% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently commented on JNJ. Barclays began coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Morgan Stanley cut their price objective on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19th. Credit Suisse Group began coverage on Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective on the stock. StockNews.com began coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Finally, Raymond James cut their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Price Performance

Shares of JNJ opened at $177.01 on Thursday. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The business’s 50 day moving average price is $168.35 and its two-hundred day moving average price is $171.28. The firm has a market cap of $462.79 billion, a PE ratio of 24.65, a price-to-earnings-growth ratio of 3.49 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same period in the prior year, the firm earned $2.60 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities analysts anticipate that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson announced that its Board of Directors has initiated a stock buyback program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s payout ratio is 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.